Does Helicobacter pylori treatment reduce recurrence of upper gastrointestinal bleeding in patients with atrial fibrillation on antithrombotic drugs?
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S132
DOI: 10.1055/s-0044-1782978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von B. J. Kim und 2 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Aims
Gastrointestinal bleeding (GIB) is a serious and potentially life-threatening complication that frequently occurs in patients taking antithrombotic therapy, including those with chronic diseases such as atrial fibrillation (AF). While previous studies have reported the effect of HP eradication on GIB in participants taking aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), its effect on GIB in AF patients taking anticoagulants is not well established. The risk of recurrent gastrointestinal bleeding (GIB) in atrial fibrillation (AF) patients on anti-thrombotic after H. pylori (HP) eradication remains poorly defined. To our knowledge, there has been no randomized controlled trial on this subject, and there is a lack of large-scale cohort studies utilizing insurance claim big data to assess the effectiveness of HP treatment in preventing rebleeding in antithrombotic-related ulcer bleeding. Therefore, there is a significant unmet need for further investigation into this important clinical issue. The aim of this study is to assess the impact of HP treatment on the risk of recurrent GIB in AF patients with previous antithrombotic-related GIB, based on nationwide health insurance claim data.
Methods
We characterized the incidences of hospitalizations for all recurrent GIB in antithrombotic users according to HP eradication therapy. Based on the nationwide claims and health database, we identified all AF patients newly diagnosed with upper GIB between 2010 and 2017. Patients were divided into three cohorts according to the anti-thrombotic use after AF diagnosis: warfarin, NOAC, and anti- platelets. The primary outcome was incident rebleeding after index GIB during follow-up.
Results
Among 250,666 AF patients first receiving NOACs or warfarin or antiplatelet from January 1, 2013 to December 31, 2018 in the overall cohort. Among a total of 2670 AF patients with upper GIB, the warfarin group (94 pairs), NOAC group (98 pairs), and anti-platelet group (218 pairs) were compared for recurrent GIB after propensity matching for the treatment of HP. During 5 years follow-up, HP treatment was closely related to recurrent GIB with marginal trend toward significance in warfarin group (hazard ratio [HR] 0.77, 95% CI 0.51- 1.18) and anti-platelet group (HR 0.89, 95% CI 0.72-1.09). Whereas, HP treatments were independently related with a lower risk of all-cause mortality in the warfarin group (HR 0.28, 95% CI 0.09-0.87) and anti-platelet group (HR 0.79, 95% CI 0.67-0.93). [ 1 ] [ 2 ] [ 3 ]
Conclusions
AF patients with GIB were not significantly associated with a lower risk for recurrent GIB after HP treatment, irrespective of the kinds of anti-thrombotic taken. However, for AF patients on anti-platelet, HP treatment reduced the risk of all-cause mortality during 5-years follow-up. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Kim, B. J., Lee, D., & Shin, S. Y. (2024). Does Helicobacter pylori treatment reduce recurrence of upper gastrointestinal bleeding in patients with atrial fibrillation on antithrombotic drugs?. Endoscopy, 56(S 02 S 02), S132. https://doi.org/10.1055/s-0044-1782978
Vancouver
Kim BJ, Lee D, Shin SY. Does Helicobacter pylori treatment reduce recurrence of upper gastrointestinal bleeding in patients with atrial fibrillation on antithrombotic drugs?. Endoscopy. 2024;56(S 02 S 02):S132. doi:10.1055/s-0044-1782978
BibTeX
@article{Kim2024,
author = {Kim, B. J. and Lee, D. and Shin, S. Y.},
title = {Does Helicobacter pylori treatment reduce recurrence of upper gastrointestinal bleeding in patients with atrial fibrillation on antithrombotic drugs?},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S132},
doi = {10.1055/s-0044-1782978}
}
EUVIMED